7 selected, source-linked Teriparatide records carrying a 2024 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
DailyMed lists Structured Product Labeling version 6 for the reviewed Teriparatide label family with a published date of 2024-12-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2024-18997, attributed to FDA and its parent HHS department, on 2024-08-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Teriparatide.
DailyMed lists Structured Product Labeling version 5 for the reviewed Teriparatide label family with a published date of 2024-07-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 218771 with status AP dated 2024-06-04, and names teriparatide among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT04522622 at 2026-07-30T18:46:20.407Z. Its registry update date was 2024-04-23, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT06303284 at 2026-07-30T18:47:17.466Z. Its registry update date was 2024-03-18, and PeptideScanner's reviewed identity mapping was teriparatide.
DailyMed lists Structured Product Labeling version 4 for the reviewed Teriparatide label family with a published date of 2024-01-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.